{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T01:00:22Z","timestamp":1789952422125,"version":"4.0.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02958-0","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:01:24Z","timestamp":1789948884000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["HSP90 shields ROC1\/RBX1 from proteasomal degradation by CHIP E3 ubiquitin ligase to promote lung adenocarcinoma"],"prefix":"10.1038","volume":"11","author":[{"given":"Lihui","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaili","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueren","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjian","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yupei","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6294-4865","authenticated-orcid":false,"given":"Shiwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6067-3923","authenticated-orcid":false,"given":"Mingsong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyi","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"2958_CR1","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2174\/156800911794519734","volume":"11","author":"L Jia","year":"2011","unstructured":"Jia, L. & Sun, Y. SCF E3 ubiquitin ligases as anticancer targets. Curr. Cancer Drug Targets 11, 347\u2013356 (2011).","journal-title":"Curr. Cancer Drug Targets"},{"key":"2958_CR2","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/416703a","volume":"416","author":"N Zheng","year":"2002","unstructured":"Zheng, N. et al. Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature 416, 703\u2013709 (2002).","journal-title":"Nature"},{"key":"2958_CR3","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s10120-013-0318-y","volume":"17","author":"K Migita","year":"2014","unstructured":"Migita, K. et al. Prognostic impact of RING box protein-1 (RBX1) expression in gastric cancer. Gastric Cancer 17, 601\u2013609 (2014).","journal-title":"Gastric Cancer"},{"key":"2958_CR4","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s13046-021-01935-5","volume":"40","author":"Q Wu","year":"2021","unstructured":"Wu, Q. et al. ROC1 promotes the malignant progression of bladder cancer by regulating p-IkappaBalpha\/NF-kappaB signaling. J. Exp. Clin. Cancer Res. 40, 158 (2021).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2958_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30707-8","volume":"13","author":"D Wu","year":"2022","unstructured":"Wu, D. et al. The Ube2m-Rbx1 neddylation-Cullin-RING-ligase proteins are essential for the maintenance of regulatory T cell fitness. Nat. Commun. 13, 3021 (2022).","journal-title":"Nat. Commun."},{"key":"2958_CR6","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/cdd.2012.113","volume":"20","author":"D Yang","year":"2013","unstructured":"Yang, D. et al. Induction of autophagy and senescence by knockdown of ROC1 E3 ubiquitin ligase to suppress the growth of liver cancer cells. Cell Death Differ. 20, 235\u2013247 (2013).","journal-title":"Cell Death Differ."},{"key":"2958_CR7","doi-asserted-by":"publisher","first-page":"4145","DOI":"10.1158\/1078-0432.CCR-15-2254","volume":"22","author":"P Chen","year":"2016","unstructured":"Chen, P. et al. Neddylation inhibition activates the extrinsic apoptosis pathway through ATF4-CHOP-DR5 axis in human esophageal cancer cells. Clin. Cancer Res. 22, 4145\u20134157 (2016).","journal-title":"Clin. Cancer Res."},{"key":"2958_CR8","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nrm.2017.20","volume":"18","author":"FH Schopf","year":"2017","unstructured":"Schopf, F. H., Biebl, M. M. & Buchner, J. The HSP90 chaperone machinery. Nat. Rev. Mol. Cell Biol. 18, 345\u2013360 (2017).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2958_CR9","doi-asserted-by":"crossref","unstructured":"Hoter, A., El-Sabban, M. E. & Naim, H. Y. The HSP90 family: structure, regulation, function, and implications in health and disease. Int. J. Mol. Sci. 19, 2560 (2018).","DOI":"10.3390\/ijms19092560"},{"key":"2958_CR10","doi-asserted-by":"publisher","first-page":"4110","DOI":"10.1172\/JCI125963","volume":"129","author":"C Pan","year":"2019","unstructured":"Pan, C. et al. Hsp90B enhances MAST1-mediated cisplatin resistance by protecting MAST1 from proteosomal degradation. J. Clin. Investig. 129, 4110\u20134123 (2019).","journal-title":"J. Clin. Investig."},{"key":"2958_CR11","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s10637-017-0556-7","volume":"36","author":"A Canonici","year":"2018","unstructured":"Canonici, A. et al. The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells. Investig. New Drugs 36, 581\u2013589 (2018).","journal-title":"Investig. New Drugs"},{"key":"2958_CR12","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s10020-021-00384-2","volume":"27","author":"J Zeng","year":"2021","unstructured":"Zeng, J., He, S. L., Li, L. J. & Wang, C. Hsp90 up-regulates PD-L1 to promote HPV-positive cervical cancer via HER2\/PI3K\/AKT pathway. Mol. Med. 27, 130 (2021).","journal-title":"Mol. Med."},{"key":"2958_CR13","doi-asserted-by":"publisher","first-page":"10832","DOI":"10.1073\/pnas.170276797","volume":"97","author":"S Sato","year":"2000","unstructured":"Sato, S., Fujita, N. & Tsuruo, T. Modulation of Akt kinase activity by binding to Hsp90. Proc. Natl. Acad. Sci. USA 97, 10832\u201310837 (2000).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2958_CR14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1080\/13543784.2017.1268599","volume":"26","author":"DS Subramaniam","year":"2017","unstructured":"Subramaniam, D. S., Warner, E. A. & Giaccone, G. Ganetespib for small cell lung cancer. Expert Opin. Investig. Drugs 26, 103\u2013108 (2017).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"2958_CR15","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1111\/cbdd.13486","volume":"93","author":"S Talaei","year":"2019","unstructured":"Talaei, S. et al. Spotlight on 17-AAG as an Hsp90 inhibitor for molecular targeted cancer treatment. Chem. Biol. Drug Des. 93, 760\u2013786 (2019).","journal-title":"Chem. Biol. Drug Des."},{"key":"2958_CR16","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1002\/ddr.22003","volume":"83","author":"F Ahmad","year":"2022","unstructured":"Ahmad, F., Sharma, S., Yadav, S. & Rathaur, S. The HSP90 inhibitor 17-AAG induced calcium-mediated apoptosis in filarial parasites. Drug Dev. Res. 83, 1867\u20131878 (2022).","journal-title":"Drug Dev. Res."},{"key":"2958_CR17","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nrc2887","volume":"10","author":"J Trepel","year":"2010","unstructured":"Trepel, J., Mollapour, M., Giaccone, G. & Neckers, L. Targeting the dynamic HSP90 complex in cancer. Nat. Rev. Cancer 10, 537\u2013549 (2010).","journal-title":"Nat. Rev. Cancer"},{"key":"2958_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.825","volume":"12","author":"F Yang","year":"2022","unstructured":"Yang, F. et al. HSP90 N-terminal inhibitors target oncoprotein MORC2 for autophagic degradation and suppress MORC2-driven breast cancer progression. Clin. Transl. Med. 12, e825 (2022).","journal-title":"Clin. Transl. Med."},{"key":"2958_CR19","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.annonc.2022.05.518","volume":"33","author":"Y Kurokawa","year":"2022","unstructured":"Kurokawa, Y. et al. Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial. Ann. Oncol. 33, 959\u2013967 (2022).","journal-title":"Ann. Oncol."},{"key":"2958_CR20","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1200\/JCO.19.00816","volume":"38","author":"RN Pillai","year":"2020","unstructured":"Pillai, R. N. et al. Randomized phase III study of ganetespib, a heat shock protein 90 inhibitor, with docetaxel versus docetaxel in advanced non-small-cell lung cancer (GALAXY-2). J. Clin. Oncol. 38, 613\u2013622 (2020).","journal-title":"J. Clin. Oncol."},{"key":"2958_CR21","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1038\/s41388-023-02745-z","volume":"42","author":"L Kang","year":"2023","unstructured":"Kang, L. et al. Control of SOX2 protein stability and tumorigenic activity by E3 ligase CHIP in esophageal cancer cells. Oncogene 42, 2315\u20132328 (2023).","journal-title":"Oncogene"},{"key":"2958_CR22","doi-asserted-by":"publisher","first-page":"20330","DOI":"10.1073\/pnas.0810571106","volume":"106","author":"ES Ehrlich","year":"2009","unstructured":"Ehrlich, E. S. et al. Regulation of Hsp90 client proteins by a Cullin5-RING E3 ubiquitin ligase. Proc. Natl. Acad. Sci. USA 106, 20330\u201320335 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2958_CR23","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/j.ymthe.2020.12.037","volume":"29","author":"Y Jia","year":"2021","unstructured":"Jia, Y. et al. Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway. Mol. Ther. 29, 1541\u20131556 (2021).","journal-title":"Mol. Ther."},{"key":"2958_CR24","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1038\/nm.3739","volume":"20","author":"D Popovic","year":"2014","unstructured":"Popovic, D., Vucic, D. & Dikic, I. Ubiquitination in disease pathogenesis and treatment. Nat. Med. 20, 1242\u20131253 (2014).","journal-title":"Nat. Med."},{"key":"2958_CR25","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1172\/JCI29715","volume":"117","author":"CA Dickey","year":"2007","unstructured":"Dickey, C. A. et al. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J. Clin. Investig. 117, 648\u2013658 (2007).","journal-title":"J. Clin. Investig."},{"key":"2958_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202302025","volume":"10","author":"Y Liao","year":"2023","unstructured":"Liao, Y. et al. HSP90beta impedes STUB1-induced ubiquitination of YTHDF2 to drive sorafenib resistance in hepatocellular carcinoma. Adv. Sci. 10, e2302025 (2023).","journal-title":"Adv. Sci."},{"key":"2958_CR27","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1084\/jem.20111117","volume":"209","author":"R Schulz","year":"2012","unstructured":"Schulz, R. et al. Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression. J. Exp. Med. 209, 275\u2013289 (2012).","journal-title":"J. Exp. Med."},{"key":"2958_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrm1547","volume":"6","author":"MD Petroski","year":"2005","unstructured":"Petroski, M. D. & Deshaies, R. J. Function and regulation of cullin-RING ubiquitin ligases. Nat. Rev. Mol. Cell Biol. 6, 9\u201320 (2005).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2958_CR29","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/embor.2013.173","volume":"14","author":"JR Lydeard","year":"2013","unstructured":"Lydeard, J. R., Schulman, B. A. & Harper, J. W. Building and remodelling Cullin-RING E3 ubiquitin ligases. EMBO Rep. 14, 1050\u20131061 (2013).","journal-title":"EMBO Rep."},{"key":"2958_CR30","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nrc1716","volume":"5","author":"L Whitesell","year":"2005","unstructured":"Whitesell, L. & Lindquist, S. L. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 5, 761\u2013772 (2005).","journal-title":"Nat. Rev. Cancer"},{"key":"2958_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05373-9","volume":"13","author":"C Peng","year":"2022","unstructured":"Peng, C. et al. HSP90 mediates the connection of multiple programmed cell death in diseases. Cell Death Dis. 13, 929 (2022).","journal-title":"Cell Death Dis."},{"key":"2958_CR32","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.biochi.2016.05.018","volume":"127","author":"S Verma","year":"2016","unstructured":"Verma, S. et al. Hsp90: Friends, clients and natural foes. Biochimie 127, 227\u2013240 (2016).","journal-title":"Biochimie"},{"key":"2958_CR33","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.2174\/092986708786242895","volume":"15","author":"A Donnelly","year":"2008","unstructured":"Donnelly, A. & Blagg, B. S. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Curr. Med. Chem. 15, 2702\u20132717 (2008).","journal-title":"Curr. Med. Chem."},{"key":"2958_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-08330-4","volume":"17","author":"C David","year":"2025","unstructured":"David, C. et al. Small-molecule inhibitor of C\u2011terminal HSP90 dimerization modulates autophagy and functions synergistically with mTOR inhibition to kill cisplatin-resistant cancer cells. Cell Death Dis. 17, 130 (2025).","journal-title":"Cell Death Dis."},{"key":"2958_CR35","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1146\/annurev-biochem-061516-044908","volume":"86","author":"I Dikic","year":"2017","unstructured":"Dikic, I. Proteasomal and autophagic degradation systems. Annu. Rev. Biochem. 86, 193\u2013224 (2017).","journal-title":"Annu. Rev. Biochem."},{"key":"2958_CR36","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/978-981-15-0602-4_25","volume":"1206","author":"Y Wang","year":"2019","unstructured":"Wang, Y. & Le, W. D. Autophagy and ubiquitin-proteasome system. Adv. Exp. Med. Biol. 1206, 527\u2013550 (2019).","journal-title":"Adv. Exp. Med. Biol."},{"key":"2958_CR37","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1038\/s41418-020-0571-7","volume":"27","author":"P Zhang","year":"2020","unstructured":"Zhang, P. et al. Ubiquitin ligase CHIP regulates OTUD3 stability and suppresses tumour metastasis in lung cancer. Cell Death Differ. 27, 3177\u20133195 (2020).","journal-title":"Cell Death Differ."},{"key":"2958_CR38","doi-asserted-by":"publisher","first-page":"31069","DOI":"10.1074\/jbc.M113.479345","volume":"288","author":"Y Matsumura","year":"2013","unstructured":"Matsumura, Y., Sakai, J. & Skach, W. R. Endoplasmic reticulum protein quality control is determined by cooperative interactions between Hsp\/c70 protein and the CHIP E3 ligase. J. Biol. Chem. 288, 31069\u201331079 (2013).","journal-title":"J. Biol. Chem."},{"key":"2958_CR39","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.molcel.2005.09.023","volume":"20","author":"M Zhang","year":"2005","unstructured":"Zhang, M. et al. Chaperoned ubiquitylation-crystal structures of the CHIP U box E3 ubiquitin ligase and a CHIP-Ubc13-Uev1a complex. Mol. Cell 20, 525\u2013538 (2005).","journal-title":"Mol. Cell"},{"key":"2958_CR40","doi-asserted-by":"publisher","first-page":"4535","DOI":"10.1128\/MCB.19.6.4535","volume":"19","author":"CA Ballinger","year":"1999","unstructured":"Ballinger, C. A. et al. Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions. Mol. Cell. Biol. 19, 4535\u20134545 (1999).","journal-title":"Mol. Cell. Biol."},{"key":"2958_CR41","doi-asserted-by":"publisher","first-page":"4974","DOI":"10.1158\/0008-5472.CAN-08-4671","volume":"69","author":"L Jia","year":"2009","unstructured":"Jia, L., Soengas, M. S. & Sun, Y. ROC1\/RBX1 E3 ubiquitin ligase silencing suppresses tumor cell growth via sequential induction of G2-M arrest, apoptosis, and senescence. Cancer Res. 69, 4974\u20134982 (2009).","journal-title":"Cancer Res."},{"key":"2958_CR42","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1038\/s41418-019-0424-4","volume":"27","author":"Y Xie","year":"2020","unstructured":"Xie, Y. et al. RBX1 prompts degradation of EXO1 to limit the homologous recombination pathway of DNA double-strand break repair in G1 phase. Cell Death Differ. 27, 1383\u20131397 (2020).","journal-title":"Cell Death Differ."},{"key":"2958_CR43","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1042\/BJ20120803","volume":"447","author":"SA Kang","year":"2012","unstructured":"Kang, S. A. et al. Hsp90 rescues PTK6 from proteasomal degradation in breast cancer cells. Biochem. J. 447, 313\u2013320 (2012).","journal-title":"Biochem. J."},{"key":"2958_CR44","doi-asserted-by":"publisher","first-page":"194931","DOI":"10.1016\/j.bbagrm.2023.194931","volume":"1866","author":"SH Choi","year":"2023","unstructured":"Choi, S. H., Cho, S. Y., Park, S. Y. & Hur, M. W. Post-translational regulation of proto-oncogene ZBTB7A expression by p53 status in cancer cells: HSP90-dependent stabilization vs. p53-KLHL20-ubiquitin proteasomal degradation. Biochim. Biophys. Acta Gene Regul. Mech. 1866, 194931 (2023).","journal-title":"Biochim. Biophys. Acta Gene Regul. Mech."},{"key":"2958_CR45","doi-asserted-by":"publisher","first-page":"6834","DOI":"10.1073\/pnas.1322412111","volume":"111","author":"RS Samant","year":"2014","unstructured":"Samant, R. S., Clarke, P. A. & Workman, P. E3 ubiquitin ligase Cullin-5 modulates multiple molecular and cellular responses to heat shock protein 90 inhibition in human cancer cells. Proc. Natl. Acad. Sci. USA 111, 6834\u20136839 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2958_CR46","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13834","volume":"22","author":"YQ Yan","year":"2023","unstructured":"Yan, Y. Q. et al. Parkin regulates microglial NLRP3 and represses neurodegeneration in Parkinson\u2019s disease. Aging Cell 22, e13834 (2023).","journal-title":"Aging Cell"},{"key":"2958_CR47","doi-asserted-by":"publisher","first-page":"4748","DOI":"10.1158\/1078-0432.CCR-20-1306","volume":"26","author":"DA Fennell","year":"2020","unstructured":"Fennell, D. A. et al. Ganetespib in combination with pemetrexed-platinum chemotherapy in patients with pleural mesothelioma (MESO-02): a phase Ib trial. Clin. Cancer Res. 26, 4748\u20134755 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2958_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00493-z","volume":"8","author":"JE Lang","year":"2022","unstructured":"Lang, J. E. et al. Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II\/III breast cancer. npj Breast Cancer 8, 128 (2022).","journal-title":"npj Breast Cancer"},{"key":"2958_CR49","doi-asserted-by":"crossref","unstructured":"Subaiea, G. et al. Ganetespib with methotrexate acts synergistically to impede NF-kappaB\/p65 signaling in human lung cancer A549 cells. Pharmaceuticals 16, 230 (2023).","DOI":"10.3390\/ph16020230"},{"key":"2958_CR50","doi-asserted-by":"publisher","first-page":"114918","DOI":"10.1016\/j.biopha.2023.114918","volume":"164","author":"S Saber","year":"2023","unstructured":"Saber, S. et al. Ganetespib (STA-9090) augments sorafenib efficacy via necroptosis induction in hepatocellular carcinoma: implications from preclinical data for a novel therapeutic approach. Biomed. Pharmacother. 164, 114918 (2023).","journal-title":"Biomed. Pharmacother."},{"key":"2958_CR51","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s10637-016-0424-x","volume":"35","author":"J Jiang","year":"2017","unstructured":"Jiang, J. et al. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery. Investig. New Drugs 35, 251\u2013259 (2017).","journal-title":"Investig. New Drugs"},{"key":"2958_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2023.1219883","volume":"11","author":"S Wurnig","year":"2023","unstructured":"Wurnig, S. et al. Development of the first geldanamycin-based HSP90 degraders. Front. Chem. 11, 1219883 (2023).","journal-title":"Front. Chem."},{"key":"2958_CR53","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/s41392-025-02444-z","volume":"10","author":"FY Yang","year":"2025","unstructured":"Yang, F. Y. et al. In vivo self-assembled nano-PROTAC for the dual degradation of AR and HSP90 to overcome castration-resistant prostate cancer resistance. Signal Transduct. Target. Ther. 10, 346 (2025).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2958_CR54","doi-asserted-by":"crossref","unstructured":"Chen, M., Chang, C., Miao, K. L., Woodley, D. T. & Li, W. Targeting Hsp90 in cancer for 25 years: failure of previous clinical trials and new hope for future therapeutics. Cells 14, 1989 (2025).","DOI":"10.3390\/cells14241989"},{"key":"2958_CR55","doi-asserted-by":"crossref","unstructured":"Kim, Y. et al. Combination strategies with HSP90 inhibitors in cancer therapy: mechanisms, challenges, and future perspectives. Pharmaceuticals 18, 1083 (2025).","DOI":"10.3390\/ph18081083"},{"key":"2958_CR56","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/jmcb\/mjz048","volume":"12","author":"Y Wu","year":"2020","unstructured":"Wu, Y. et al. The molecular chaperone Hsp90alpha deficiency causes retinal degeneration by disrupting Golgi organization and vesicle transportation in photoreceptors. J. Mol. Cell Biol. 12, 216\u2013229 (2020).","journal-title":"J. Mol. Cell Biol."},{"key":"2958_CR57","doi-asserted-by":"crossref","unstructured":"Jia, S., Maurya, N., Blagg, B. S. J. & Lu, X. Hsp90 pan and isoform-selective inhibitors as sensitizers for cancer immunotherapy. Pharmaceuticals 18, 1025 (2025).","DOI":"10.3390\/ph18071025"},{"key":"2958_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2022.102700","volume":"298","author":"K Donahue","year":"2022","unstructured":"Donahue, K. et al. Diptoindonesin G is a middle domain HSP90 modulator for cancer treatment. J. Biol. Chem. 298, 102700 (2022).","journal-title":"J. Biol. Chem."},{"key":"2958_CR59","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.isci.2019.05.033","volume":"16","author":"D Chen","year":"2019","unstructured":"Chen, D. et al. A multidimensional characterization of E3 ubiquitin ligase and substrate interaction network. iScience 16, 177\u2013191 (2019).","journal-title":"iScience"},{"key":"2958_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54919-2","volume":"15","author":"F Zhu","year":"2024","unstructured":"Zhu, F. et al. CRL3(Keap1) E3 ligase facilitates ubiquitin-mediated degradation of oncogenic SRX to suppress colorectal cancer progression. Nat. Commun. 15, 10536 (2024).","journal-title":"Nat. Commun."},{"key":"2958_CR61","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202503322","volume":"12","author":"Y Yan","year":"2025","unstructured":"Yan, Y. et al. Splicing shift of RAC1 accelerates tumorigenesis and defines a potent therapeutic target in lung cancer. Adv. Sci. 12, e03322 (2025).","journal-title":"Adv. Sci."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02958-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02958-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02958-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:01:27Z","timestamp":1789948887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02958-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2958"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02958-0","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"18 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no potential conflicts of interest. L.J. is the editorial board member of\n                      Signal Transduction and Targeted Therapy\n                      , but he has not been involved in the process of manuscript handling.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"394"}}